Clinical Cardiology Alert – March 1, 2023
March 1, 2023
View Issues
-
Surgical Risk of Mitral Valve Repair, Updated
A contemporary update of the Society of Thoracic Surgeons risk calculator for operative mortality and morbidity in nonemergent primary mitral valve repair for regurgitation shows an operative mortality rate of 1.2%, with a conversion to replacement of 6%, in more than 53,000 patients.
-
ECMO-Supported CPR Disappoints for Treating Out-of-Hospital Cardiac Arrest
For patients with out-of-hospital cardiac arrest that was refractory to initial resuscitation efforts, adding extracorporeal membrane oxygenation to standard CPR did not result in a significant improvement in survival with favorable neurologic outcome.
-
How to Diagnose ATTR Cardiac Amyloidosis
A retrospective study of patients with confirmed cardiac amyloidosis showed negative light chain biomarkers and a typical pattern of cardiac amyloid on cardiac MRI was highly specific for the diagnosis of the transthyretin subtype and may obviate the need for further testing before starting treatment.
-
Long-Term Maintenance Therapy After Percutaneous Coronary Intervention
An extended six-year follow-up of the HOST-EXAM study revealed the consistent benefit of the primary endpoint of fewer major cardiovascular events and less bleeding with clopidogrel vs. low-dose aspirin monotherapy in post-percutaneous coronary intervention patients who were on dual antiplatelet therapy for one year.
-
Effectiveness of Dietary Supplements on Lipid and Inflammatory Biomarkers
In a comparison of rosuvastatin 5 mg/day, six common dietary supplements marketed for improving heart health, and placebo, none reduced high-sensitivity C-reactive protein levels. Only rosuvastatin significantly reduced LDL cholesterol levels compared to placebo.